



Erratum for Peloquin et al., “Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis”

C. A. Peloquin,^a G. E. Velásquez,^{b,c} L. Lecca,^{c,d} R. I. Calderón,^d J. Coit,^b
M. Milstein,^b E. Osso,^b J. Jimenez,^d K. Tintaya,^d E. Sanchez Garavito,^e
D. Vargas Vasquez,^f C. D. Mitnick,^{c,g} G. Davies^h

University of Florida College of Pharmacy and Emerging Pathogens Institute, Gainesville, Florida, USA^a; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA^b; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA^c; Socios En Salud, Lima, Peru^d; Hospital Nacional Sergio Bernales, Lima, Peru^e; Hospital Nacional Hipólito Unanue, Lima, Peru^f; Partners In Health, Boston, Massachusetts, USA^g; Institutes of Infection and Global Health and Translational Medicine, University of Liverpool, Liverpool, United Kingdom^h

Volume 61, no. 8, e00038-17, 2017, <https://doi.org/10.1128/AAC.00038-17>. Page 1, second line from the bottom: “0.88 to 1.414 mg/liter” should read “0.088 to 1.414 mg/liter.”

Citation Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Garavito ES, Vasquez DV, Mitnick CD, Davies G. 2017. Erratum for Peloquin et al, “Pharmacokinetic evidence from the HIRIF trial to support increased doses of rifampin for tuberculosis.” *Antimicrob Agents Chemother* 61:e01524-17. <https://doi.org/10.1128/AAC.01524-17>.

Copyright © 2017 American Society for Microbiology. All Rights Reserved.